These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3125399)

  • 1. Effect of human growth hormone-releasing hormone on GH secretion in Cushing's syndrome and non-endocrine disease patients treated with glucocorticoids.
    Hotta M; Shibasaki T; Masuda A; Imaki T; Sugino N; Demura H; Ling N; Shizume K
    Life Sci; 1988; 42(9):979-84. PubMed ID: 3125399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.
    Giustina A; Bossoni S; Bussi AR; Pozzi A; Wehrenberg WB
    Endocr Res; 1993 Mar; 19(1):47-56. PubMed ID: 7681769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome.
    Leal-Cerro A; Pereira JL; Garcia-Luna PP; Astorga R; Cordido F; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):291-5. PubMed ID: 2225484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
    Giustina A; Bossoni S; Bodini C; Ferrari C; Pizzocolo G; Scalvini T; Schettino M; Wehrenberg WB
    Horm Res; 1991; 35(3-4):99-103. PubMed ID: 1806475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The inter- and intra-subject variabilities of plasma GH response to human growth hormone-releasing hormone (1-44) NH2 in men.
    Hotta M; Shibasaki T; Masuda A; Imaki T; Wakabayashi I; Demura H; Ling N; Shizume K
    Endocrinol Jpn; 1985 Oct; 32(5):673-80. PubMed ID: 3937723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
    Leal-Cerro A; Venegas E; Garcia-Pesquera F; Jimenez LM; Astorga R; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of impaired growth hormone secretion in patients with Cushing's disease.
    Takahashi H; Bando H; Zhang C; Yamasaki R; Saito S
    Acta Endocrinol (Copenh); 1992 Jul; 127(1):13-7. PubMed ID: 1519417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human pancreatic growth hormone releasing hormone fails to stimulate human growth hormone both in Cushing's disease and in Cushing's syndrome due to adrenocortical adenoma.
    Smals AE; Pieters GF; Smals AG; Benraad TJ; Kloppenborg PW
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):401-7. PubMed ID: 3091296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone responses to growth hormone-releasing hormone and clonidine in dogs with Cushing's syndrome.
    Regnier A; Garnier F
    Res Vet Sci; 1995 Mar; 58(2):169-73. PubMed ID: 7761697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
    Mukherjee A; Murray RD; Teasdale GM; Shalet SM
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
    Tzanela M; Karavitaki N; Stylianidou C; Tsagarakis S; Thalassinos NC
    Clin Endocrinol (Oxf); 2004 Mar; 60(3):309-14. PubMed ID: 15008995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
    Leal-Cerro A; Jimenez LM; Astorga R; Fernandez-Lopez I; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ghrelin is no longer able to stimulate growth hormone secretion in patients with Cushing's syndrome but instead induces exaggerated corticotropin and cortisol responses.
    Leal-Cerro A; Torres E; Soto A; Dios E; Deghenghi R; Arvat E; Ghigo E; Dieguez C; Casanueva FF
    Neuroendocrinology; 2002 Dec; 76(6):390-6. PubMed ID: 12566947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone.
    Giustina A; Bussi AR; Jacobello C; Wehrenberg WB
    J Clin Endocrinol Metab; 1995 Jan; 80(1):122-9. PubMed ID: 7829600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease.
    Pecori Giraldi F; Andrioli M; De Marinis L; Bianchi A; Giampietro A; De Martin M; Sacco E; Scacchi M; Pontecorvi A; Cavagnini F
    Eur J Endocrinol; 2007 Feb; 156(2):233-9. PubMed ID: 17287413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy.
    Giustina A; Buffoli MG; Bussi AR; Doga M; Girelli A; Pizzocolo G; Pozzi A; Wehrenberg WB
    Horm Metab Res; 1992 May; 24(5):240-3. PubMed ID: 1398465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man.
    Laue L; Chrousos GP; Loriaux DL; Barnes K; Munson P; Nieman L; Schaison G
    J Clin Endocrinol Metab; 1988 Feb; 66(2):290-3. PubMed ID: 2828406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.